ABOUT ELITE
Overview
Our Facility
Management & Key Employees
Our Board
Careers
PRODUCTS
PIPELINE
Generic
Branded
TECHNOLOGY
Technology Overview
How It Works
One Bead System
Two Bead System
INVESTOR RELATIONS
Press Releases
Events & Presentations
SEC Filings
Shareholder Meeting
Governance Documents
Investor Contacts
Email Alerts
HOME
|
CAREERS
|
CONTACT
|
NEWS
|
Skip to content
About Elite
Overview
Management & Key Employees
Our Board
Careers
Products
Pipeline
Generic
Branded
Technology
Technology Overview
How It Works
One Bead System
Two Bead System
Investor Relations
Press Releases
Events & Presentations
SEC Filings
Shareholder Meeting
Governance Documents
Investor Contacts
Email Alerts
Investor Relations
Press Releases
Events &Presentations
SEC Filings
ShareholderMeeting
GovernanceDocuments
Investor Contacts
Email Alerts
Press Releases
Select:
Show All
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Archived
May 25, 2017
Elite Pharmaceuticals' SequestOx™ Study Results Expected in July
May 22, 2017
Elite Pharmaceuticals Acquires Trimipramine ANDA
Apr 04, 2017
Elite Pharmaceuticals Files ANDA for Pain Product
Mar 13, 2017
Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study for Reformulated SequestOx™
Feb 09, 2017
Elite Pharmaceuticals, Inc. Reports Results for Third Quarter of Fiscal Year 2017
Feb 07, 2017
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017
Jan 23, 2017
Elite Reports On SequestOx™ FDA End-of-Review Meeting
Jan 17, 2017
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®
Dec 22, 2016
Elite Provides Update on SequestOx™ New Drug Application
Nov 09, 2016
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2017 and Provides Conference Call Information
8
9
10
11
12
13
14
15
16
17
18
<<
<
>
>>
Back to top
Privacy
